Clinical trials: Phosphorus Metabolism
Kidney Failure, Chronic, End-Stage Renal Disease
Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
The purpose of this study is to perform a randomized, controlled clinical trial to investigate if the phosphate binder sevelamer can improve insulin resistance and glucose handling in patients receiving maintenance hemodialysis.
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Insulin Resistance, Hyperphosphatemia
- Trial name
- SIR (NCT00837655)
- Testing
- Sevelamer, Calcium carbonate
- Where
- 2 sites in Sweden
- Sponsor
- Karolinska Institutet
Hyperphosphatemia
Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
- Trial name
- NCT06206135
- Testing
- the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hyperphosphataemia, Phosphorus
Phosphate Diet Strategies to Lower Blood Phosphate in Dialysis Patients
Raised phosphate levels in the blood (hyperphosphatemia) are frequently observed in hemodialysis patients with chronic kidney failure.
- Conditions
- Hyperphosphataemia, Phosphorus, Diet Therapy, Chronic Kidney Disease 5D
- Trial name
- NCT07180069
- Testing
- diet education
- Where
- Iraq
- Volunteers
- 200 people
- Sponsor
- Kufa University
Hyperphosphatemia, End-stage Renal Disease
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).
- Conditions
- Hyperphosphatemia, End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
- Trial name
- NCT00967993
- Testing
- ferric citrate
- Where
- 3 sites in Israel
- Volunteers
- 22 people
- Sponsor
- Keryx Biopharmaceuticals
X-linked Hypophosphatemia
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.
- Trial name
- NCT02526160
- Testing
- burosumab
- Where
- 25 sites in United States, France and 5 more
- Volunteers
- 134 people
- Sponsor
- Kyowa Kirin, Inc.
Hyperphosphataemia, Chronic Kidney Disease
Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
The primary objective of this study is to assess in a post-approval clinical setting the safety profile of sevelamer carbonate (Renvela®) tablets and powder in adult hyperphosphataemic chronic kidney disease (CKD) patients not on…
- Trial name
- NCT01857024
- Testing
- sevelamer carbonate (Renvela®)
- Where
- 26 sites in Austria, Denmark and 5 more
- Volunteers
- 210 people
- Sponsor
- Genzyme, a Sanofi Company
Haemodialyzed Patients, Hyperphosphatemia
Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
End-stage renal disease (ESRD) is a state of increased arterial stiffness of extensive vessel calcifications, compared with the non-renal population.
- Trial name
- NCT00364000
- Testing
- Calcium acetate, Sevelamer
- Where
- 2 sites in Romania
- Sponsor
- Romanian Society of Nephrology
X-linked Hypophosphatemia
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
The objectives of the study are to: Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants Establish the safety profile of burosumab for the treatment of…
- Trial name
- NCT02163577
- Testing
- burosumab
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 52 people
- Sponsor
- Kyowa Kirin, Inc.
Hyperphosphatemia
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings
- Trial name
- NCT06186934
- Testing
- the standard-dose group (4 g/day)
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Hyperphosphatemia
Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for…
- Trial name
- FOSRENOL-CAPD (NCT01412398)
- Testing
- Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
- Where
- Japan
- Volunteers
- 446 people
- Sponsor
- Bayer
Hyperphosphatemia, Chronic Kidney Disease
PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum
The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG…
- Trial name
- NCT01319578
- Testing
- K2CG chewing gum
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Denver Nephrologists, P.C.
Chronic Kidney Disease(CKD), Hyperphosphatemia
Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease
As Chronic Kidney Disease (CKD) progresses normophosphatemia is maintained by increasing the per nephron urinary phosphorus excretion.
- Conditions
- Chronic Kidney Disease(CKD), Hyperphosphatemia, Blood Pressure
- Trial name
- CKD (NCT04579315)
- Testing
- Intervention group; NNRD group
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Bo Feldt-Rasmussen
Kidney Diseases
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.
- Trial name
- NCT00452478
- Testing
- Lanthanum carbonate
- Where
- 14 sites in Austria, Belgium and 4 more
- Volunteers
- 68 people
- Sponsor
- Shire
Hypophosphatemia
Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
Fibroblast froth factors (FGFs) are humoral factors identified by their ability to stimulate cell proliferation1. They play different roles in the regulation of cell proliferation, differentiation and function.
- Trial name
- NCT01660308
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Healthy
Impact of Food Additives on Phosphorus Metabolism
The purpose of the study is to learn more about how phosphorus-based food additives affect phosphorus metabolism in people with normal kidney function.
- Trial name
- NCT01394146
- Testing
- Research diet
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Degenerative Heart Valve Disease, Heart Valve Calcification
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD).
- Conditions
- Degenerative Heart Valve Disease, Heart Valve Calcification, Chronic Kidney Disease(CKD), Calcium-Phosphorus Metabolism Disorders
- Trial name
- NCT06660524
- Testing
- Sevelamer, Calcium carbonate
- Where
- China
- Volunteers
- 196 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hyperphosphatemia
Phosphorus Improvement Pilot Study
Specific Aim: To determine the effect of a phosphorus additives educational intervention on serum phosphorus levels. Hypothesis: Educating dialysis patients regarding phosphate containing additives will result in improved serum…
- Trial name
- NCT00583570
- Testing
- dietary education
- Volunteers
- 279 people
- Sponsor
- MetroHealth Medical Center
Heart Failure
Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study
Heart failure (HF) is a major public health problem, which affects about 5 million Americans.HF is when the heart muscle does not pump as much blood as the body needs.
- Trial name
- CAPRICORN (NCT00853541)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
X-linked Hypophosphatemia
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
X-linked hypophosphatemia (XLH) is the most common form of heritable rickets. Current treatments include active vitamin D metabolites (e.g. calcitriol) and phosphate salts.
- Trial name
- NCT03820518
- Testing
- Calcitriol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital